Plumbagin inhibits prostate cancer development in TRAMP mice via targeting PKCε, Stat3 and neuroendocrine markers

Carcinogenesis

Volumn 33, Issue 12, 2012, Pages 2586-2592

  Hafeez, Bilal Bin ^a   Zhong, Weixiong ^a   Mustafa, Ala ^a   Fischer, Joseph W ^a   Witkowsky, Olya ^a   Verma, Ajit K ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; CYCLINE; PLUMBAGIN; PROTEIN KINASE C EPSILON; STAT3 PROTEIN; SYNAPTOPHYSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER SIZE; CARCINOGENESIS; CONTROLLED STUDY; HISTOPATHOLOGY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING;

ADENOCARCINOMA; ANIMALS; ANTICARCINOGENIC AGENTS; ANTIGENS, POLYOMAVIRUS TRANSFORMING; CHROMOGRANIN A; DISEASE MODELS, ANIMAL; MALE; MICE; MICE, TRANSGENIC; NAPHTHOQUINONES; PHOSPHORYLATION; PROLIFERATING CELL NUCLEAR ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN KINASE C-EPSILON; STAT3 TRANSCRIPTION FACTOR; SYNAPTOPHYSIN;

EID: 84870326497     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs291     Document Type: Article

References (37)

1. Siegel, R. et al. (2012) Cancer statistics, 2012. CA Cancer J. Clin., 62, 10-29.
2. Albertsen, P. (2008) Predicting survival for men with clinically localized prostate cancer: what do we need in contemporary practice? Cancer, 112, 1-3.
3. So, A. et al. (2005) Mechanisms of the development of androgen independence in prostate cancer. World J. Urol., 23, 1-9.
4. Wattenberg, L.W. et al. (2000) Chemoprevention of pulmonary carcinogenesis by brief exposures to aerosolized budesonide or beclomethasone dipropionate and by the combination of aerosolized budesonide and dietary myo-inositol. Carcinogenesis, 21, 179-182.
5. Kim, H. et al. (2004) Chemoprevention by grape seed extract and genistein in carcinogen-induced mammary cancer in rats is diet dependent. J. Nutr., 134(12 suppl.), 3445S-3452S.
6. Adhami, V.M. et al. (2012) Oral infusion of pomegranate fruit extract inhibits prostate carcinogenesis in the TRAMP model. Carcinogenesis, 33, 644-651.
7. Shukla, S. et al. (2007) Blockade of beta-catenin signaling by plant flavonoid apigenin suppresses prostate carcinogenesis in TRAMP mice. Cancer Res., 67, 6925-6935.
8. Sandur, S.K. et al. (2006) Plumbagin (5-hydroxy-2-methyl-1, 4-naphthoquinone) suppresses NF-kappaB activation and NF-kappaB-regulated gene products through modulation of p65 and IkappaBalpha kinase activation, leading to potentiation of apoptosis induced by cytokine and chemotherapeutic agents. J. Biol. Chem., 281, 17023-17033.
9. Padhye, S. et al. (2010) Perspectives on medicinal properties of plumbagin and its analogs. Med. Res. Rev. [Epub ahead of print].
10. Son, T.G. et al. (2010) Plumbagin, a novel Nrf2/ARE activator, protects against cerebral ischemia. J. Neurochem., 112, 1316-1326.
11. Sugie, S. et al. (1998) Inhibitory effects of plumbagin and juglone on azoxymethane-induced intestinal carcinogenesis in rats. Cancer Lett., 127, 177-183.
12. Kuo, P.L. et al. (2006) Plumbagin induces G2-M arrest and autophagy by inhibiting the AKT/mammalian target of rapamycin pathway in breast cancer cells. Mol. Cancer Ther., 5, 3209-3221.
13. Hsu, Y.L. et al. (2006) Plumbagin (5-hydroxy-2-methyl-1, 4-naphthoquinone) induces apoptosis and cell cycle arrest in A549 cells through p53 accumulation via c-Jun NH2-terminal kinase-mediated phosphorylation at serine 15 in vitro and in vivo. J. Pharmacol. Exp. Ther., 318, 484-494.
14. Wang, C.C. et al. (2008) Plumbagin induces cell cycle arrest and apoptosis through reactive oxygen species/c-Jun N-terminal kinase pathways in human melanoma A375.S2 cells. Cancer Lett., 259, 82-98.
15. Sand, J.M. et al. (2012) Plumbagin (5-hydroxy-2-methyl-1, 4-naphthoquinone), isolated from Plumbago zeylanica, inhibits ultraviolet radiationinduced development of squamous cell carcinomas. Carcinogenesis, 33, 184-190.
16. Chen, C.A. et al. (2009) Plumbagin, isolated from Plumbago zeylanica, induces cell death through apoptosis in human pancreatic cancer cells. Pancreatology, 9, 797-809.
17. Hafeez, B.B. et al. (2012) Plumbagin, a plant derived natural agent inhibits the growth of pancreatic cancer cells in in vitro and in vivo via targeting EGFR, Stat3 and NF-κB signaling pathways. Int. J. Cancer, doi: 10.1002/ijc.27478 [Epub ahead of print].
18. Aziz, M.H. et al. (2008) Plumbagin, a medicinal plant-derived naphthoquinone, is a novel inhibitor of the growth and invasion of hormone-refractory prostate cancer. Cancer Res., 68, 9024-9032.
19. Powolny, A.A. et al. (2008) Plumbagin-induced apoptosis in human prostate cancer cells is associated with modulation of cellular redox status and generation of reactive oxygen species. Pharm. Res., 25, 2171-2180.
20. Hafeez, B.B. et al. (2011) Genetic ablation of PKC epsilon inhibits prostate cancer development and metastasis in transgenic mouse model of prostate adenocarcinoma. Cancer Res., 71, 2318-2327.
21. Hurwitz, A.A. et al. (2001) The TRAMP mouse as a model for prostate cancer. Curr. Protoc. Immunol., Chapter 20, Unit 20.5.
22. Aziz, M.H. et al. (2007) Protein kinase C epsilon interacts with signal transducers and activators of transcription 3 (Stat3), phosphorylates Stat3Ser727, and regulates its constitutive activation in prostate cancer. Cancer Res., 67, 8828-8838.
23. Aziz, M.H. et al. (2010) Protein kinase C epsilon mediates Stat3Ser727 phosphorylation, Stat3-regulated gene expression, and cell invasion in various human cancer cell lines through integration with MAPK cascade (RAF-1, MEK1/2, and ERK1/2). Oncogene, 29, 3100-3109.
24. Zhong, W. et al. (2008) Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia. Clin. Invest. Med., 31, 8-15.
25. Liu, C. et al. (2011) Prognostic impact of nm23-H1 and PCNA expression in pathologic stage I non-small cell lung cancer. J. Surg. Oncol., 104, 181-186.
26. Zhao, H. et al. (2011) Targeting tyrosine phosphorylation of PCNA inhibits prostate cancer growth. Mol. Cancer Ther., 10, 29-36.
27. Chiaverotti, T. et al. (2008) Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am. J. Pathol., 172, 236-246.
28. Pan, Q. et al. (2005) Protein kinase C epsilon is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy. Cancer Res., 65, 8366-8371.
29. Martínez-Gimeno, C. et al. (1995) Alterations in levels of different protein kinase C isotypes and their influence on behavior of squamous cell carcinoma of the oral cavity: epsilon PKC, a novel prognostic factor for relapse and survival. Head Neck, 17, 516-525.
30. Aziz, M.H. et al. (2007) Protein kinase C epsilon, which sensitizes skin to sun's UV radiation-induced cutaneous damage and development of squamous cell carcinomas, associates with Stat3. Cancer Res., 67, 1385-1394.
31. Koren, R. et al. (2004) Expression of protein kinase C isoenzymes in benign hyperplasia and carcinoma of prostate. Oncol. Rep., 11, 321-326.
32. Wu, D. et al. (2002) Protein kinase cepsilon has the potential to advance the recurrence of human prostate cancer. Cancer Res., 62, 2423-2429.
33. Benavides, F. et al. (2011) Transgenic overexpression of PKCε in the mouse prostate induces preneoplastic lesions. Cell Cycle, 10, 268-277.
34. Meshki, J. et al. (2010) Regulation of prostate cancer cell survival by protein kinase C epsilon involves bad phosphorylation and modulation of the TNFalpha/JNK pathway. J. Biol. Chem., 285, 26033-26040.
35. Wu, D. et al. (2004) Integrin signaling links protein kinase Cepsilon to the protein kinase B/Akt survival pathway in recurrent prostate cancer cells. Oncogene, 23, 8659-8672.
36. McJilton, M.A. et al. (2003) Protein kinase Cepsilon interacts with Bax and promotes survival of human prostate cancer cells. Oncogene, 22, 7958-7968.
37. Palmgren, J.S. et al. (2007) Unusual and underappreciated: small cell carcinoma of the prostate. Semin. Oncol., 34, 22-29.